PubMed Health⌕ Search

PubMed · 5499031

Signals from cones.

Abstract

1. We have studied red and green cones by contrast flash inhibition and found them both to be very similar to rods in their response to flash energy, except that all light quantities must be some 100-fold greater in cones for the same effect.2. Using the methods of a previous paper (A.R.T. a) where no backgrounds were employed, we plotted log test flash lambda against log surround flash varphi with criterion that lambda should just be detected. The experiment was repeated with a ;windmill stop' interposed in the varphi flash which reduced its area symmetrically to (1/8). From these two curves it is possible to extract the relation between N, the inhibitory signal, and varphi, the test flash. It isN = varphi/(varphi+sigma),where sigma, the semi-saturation constant, is about 4.5 log td sec.3. Using the methods of (A.R.T. b) where backgrounds were studied, we measured the increment threshold for the surround flash varphi against its background theta using as criterion not that varphi should just be seen but that it should generate a fixed inhibitory signal N so that the fixed test flash lambda could just be seen.4. This increment threshold curve resembled the Aguilar & Stiles (1954) curve for rods, showed saturation and a complete symmetry about the 45 degrees line through the point with co-ordinates (log theta(D), log sigma).5. These results imply that the cone signal N is related to flash varphi and steady background theta by [Formula: see text], where theta(D) is receptor noise (= eigengrau), and varphi and theta are expressed in units of quantum catch.6. The ordinary increment threshold for cones does not show saturation because a steady saturating background bleaches all the pigment away. When the background is presented for only 100 msec with dark pauses between, no great bleaching occurs and saturation is seen.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Alpern, W A Rushton, S Torii. 1970. Signals from cones.. https://doi.org/10.1113/jphysiol.1970.sp009073

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗